Definition

A personalized cancer vaccine comprised of a not yet disclosed oncolytic virus encoding tumor-specific neoantigens that have been identified through genetic sequencing of a patient’s tumor cells, with potential immunostimulatory and antineoplastic activities. Upon administration, the neoantigen-encoding personalized virus-2 (PSV-2) infects cells and expresses the tumor-specific neoantigens (TSNAs). This stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the TSNAs, leading to tumor cell lysis.